679 related articles for article (PubMed ID: 26340986)
41. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
42. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
[TBL] [Abstract][Full Text] [Related]
43. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
44. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
45. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma.
Ozsan GH; Micallef IN; Dispenzieri A; Kumar S; Lacy MQ; Dingli D; Hayman SR; Buadi FK; Wolf RC; Gastineau DA; Hogan WJ; Gertz MA
Am J Hematol; 2012 Jan; 87(1):1-4. PubMed ID: 21959988
[TBL] [Abstract][Full Text] [Related]
46. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
[TBL] [Abstract][Full Text] [Related]
47. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
[TBL] [Abstract][Full Text] [Related]
48. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
49. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
[TBL] [Abstract][Full Text] [Related]
50. Appropriate timing of G-CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT.
Xu L; Chang C; Li X; Gan W
J Clin Apher; 2009; 24(6):232-7. PubMed ID: 19899124
[TBL] [Abstract][Full Text] [Related]
51. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
52. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199
[TBL] [Abstract][Full Text] [Related]
53. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
[TBL] [Abstract][Full Text] [Related]
54. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.
Jelinek T; Adamusova L; Popkova T; Tvrda I; Smejkalova J; Simicek M; Salounova D; Kascak M; Mihalyova J; Plonkova H; Duras J; Navratil M; Hajek R; Koristek Z
Bone Marrow Transplant; 2019 Jul; 54(7):1107-1114. PubMed ID: 30459429
[TBL] [Abstract][Full Text] [Related]
55. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
Desikan KR; Jagannath S; Siegel D; Nelson J; Bracy D; Barlogie B; Tricot G
Leuk Lymphoma; 1998 Feb; 28(5-6):501-8. PubMed ID: 9613979
[TBL] [Abstract][Full Text] [Related]
56. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
[TBL] [Abstract][Full Text] [Related]
57. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.
Desikan KR; Barlogie B; Jagannath S; Vesole DH; Siegel D; Fassas A; Munshi N; Singhal S; Mehta J; Tindle S; Nelson J; Bracy D; Mattox S; Tricot G
J Clin Oncol; 1998 Apr; 16(4):1547-53. PubMed ID: 9552064
[TBL] [Abstract][Full Text] [Related]
58. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
Gazitt Y; Akay C; Thomas C
Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
[TBL] [Abstract][Full Text] [Related]
59. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
60. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F
Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]